Kyle Lauren Poulsen

Kyle Lauren Poulsen

Auto-generated profile, based on publicly available information

Kyle Lauren Poulsen

Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
XWXiaoqin Wu
Xiaoqin Wu
KPKyle L. Poulsen
Kyle L. Poulsen
Carlos Sanz GarcíaCarlos Sanz García
Carlos Sanz García
EHEmily Huang
Emily Huang
MMMegan R. McMullen
Megan R. McMullen
LNLaura E Nagy
Laura E Nagy

5 March 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
LXLong Xu
Long Xu
YYYang Yang
Yang Yang
Yankai WenYankai Wen
Yankai Wen
JJJong-Min Jeong
Jong-Min Jeong
CEChristoph Emontzpohl
Christoph Emontzpohl
CJCynthia Ju
Cynthia Ju

1 November 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
VMVeronica Marin
Veronica Marin
KPKyle Poulsen
Kyle Poulsen
GOGemma Odena
Gemma Odena
MMMegan R. McMullen
Megan R. McMullen
JAJose Altamirano
Jose Altamirano
LNLaura E Nagy
Laura E Nagy

11 November 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
EFErika Y. Faraoni
Erika Y. Faraoni
BOBaylee J. O'BRien
Baylee J. O'BRien
LSLincoln N. Strickland
Lincoln N. Strickland
BOBaron K. Osborn
Baron K. Osborn
VMVictoria Mota
Victoria Mota
JBJennifer M. Bailey-Lundberg
Jennifer M. Bailey-Lundberg
Pancreatic ductal adenocarcinoma (PDAC) presents a 5-year overall survival rate of 11%, despite efforts to improve clinical outcomes in the past two decades. Therapeutic resistance is a hallmark of this disease, due to its dense and suppressive tumor microenvironment (TME). Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising local ablative and potential immunomodulatory therapy for PDAC. In this study, we performed RFA in a preclinical tumor-bearing KrasG12D; Trp53R172H/+; Pdx1:Cre (KPC) syngeneic model, analyzed local and abscopal affects after RFA and compared our findings with resected PDAC specimens. We found that RFA reduced PDAC tumor progression in vivo and promoted strong TME remodeling. In addition, we discovered tumor-infiltrating neutrophils determined abscopal effects. Using imaging mass cytometry, we showed that RFA elevated dendritic cell numbers in RFA-treated tumors and promoted a significant CD4+ and CD8+ T-cell abscopal response. In addition, RFA elevated levels of programmed death-ligand 1 (PD-L1) and checkpoint blockade inhibition targeting PD-L1 sustained tumor growth reduction in the context of RFA. This study indicates RFA treatment, which has been shown to increase tumor antigen shedding, promotes antitumor immunity. This is critical in PDAC where recent clinical immunotherapy trials have not resulted in substantial changes in overall survival.

31 January 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
EFErika Y. Faraoni
Erika Y. Faraoni
KSKanchan Singh
Kanchan Singh
VCVidhi Chandra
Vidhi Chandra
OROlivereen Le Roux
Olivereen Le Roux
YDYulin Dai
Yulin Dai
JBJennifer M. Bailey-Lundberg
Jennifer M. Bailey-Lundberg
The microenvironment that surrounds pancreatic ductal adenocarcinoma (PDAC) is profoundly desmoplastic and immunosuppressive. Understanding triggers of immunosuppression during the process of pancreatic tumorigenesis would aid in establishing targets for effective prevention and therapy. Here, we interrogated differential molecular mechanisms dependent on cell of origin and subtype that promote immunosuppression during PDAC initiation and in established tumors. Transcriptomic analysis of cell-of-origin–dependent epithelial gene signatures revealed that Nt5e/CD73, a cell-surface enzyme required for extracellular adenosine generation, is one of the top 10% of genes overexpressed in murine tumors arising from the ductal pancreatic epithelium as opposed to those rising from acinar cells. These findings were confirmed by IHC and high-performance liquid chromatography. Analysis in human PDAC subtypes indicated that high Nt5e in murine ductal PDAC models overlaps with high NT5E in human PDAC squamous and basal subtypes, considered to have the highest immunosuppression and worst prognosis. Multiplex immunofluorescent analysis showed that activated CD8+ T cells in the PDAC tumor microenvironment express high levels of CD73, indicating an opportunity for immunotherapeutic targeting. Delivery of CD73 small-molecule inhibitors through various delivery routes reduced tumor development and growth in genetically engineered and syngeneic mouse models. In addition, the adenosine receptor Adora2b was a determinant of adenosine-mediated immunosuppression in PDAC. These findings highlight a molecular trigger of the immunosuppressive PDAC microenvironment elevated in the ductal cell of origin, linking biology with subtype classification, critical components for PDAC immunoprevention and personalized approaches for immunotherapeutic intervention. Significance: Ductal-derived pancreatic tumors have elevated epithelial and CD8+GZM+ T-cell CD73 expression that confers sensitivity to small-molecule inhibition of CD73 or Adora2b to promote CD8+ T-cell–mediated tumor regression. See related commentary by DelGiorno, p. 977

1 July 2018 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
RMRebecca L. McCullough
Rebecca L. McCullough
MMMegan R. McMullen
Megan R. McMullen
MSMegan M. Sheehan
Megan M. Sheehan
KPKyle L. Poulsen
Kyle L. Poulsen
SRSanjoy Roychowdhury
Sanjoy Roychowdhury
LNLaura E Nagy
Laura E Nagy
Complement plays a crucial role in microbial defense and clearance of apoptotic cells. Emerging evidence suggests complement is an important contributor to alcoholic liver disease. While complement component 1, Q subcomponent (C1q)-dependent complement activation contributes to ethanol-induced liver injury, the role of the alternative pathway in ethanol-induced injury is unknown. Activation of complement via the classical and alternative pathways was detected in alcoholic hepatitis patients. Female C57BL/6J [wild type (WT)], C1q-deficient ( C1qa−/−, lacking classical pathway activation), complement protein 4-deficient ( C4−/−, lacking classical and lectin pathway activation), complement factor D-deficient ( FD−/−, lacking alternative pathway activation), and C1qa/FD−/−(lacking classical and alternative pathway activation) mice were fed an ethanol-containing liquid diet or pair-fed control diet for 4 or 25 days. Following chronic ethanol exposure, liver injury, steatosis, and proinflammatory cytokine expression were increased in WT but not C1qa−/−, C4−/−, or C1qa/FD−/−mice. In contrast, liver injury, steatosis, and proinflammatory mediators were robustly increased in ethanol-fed FD−/−mice compared with WT mice. Complement activation, assessed by hepatic accumulation of C1q and complement protein 3 (C3) cleavage products (C3b/iC3b/C3c), was evident in livers of WT mice in response to both short-term and chronic ethanol. While C1q accumulated in ethanol-fed FD−/−mice (short term and chronic), C3 cleavage products were detected after short-term but not chronic ethanol. Consistent with impaired complement activation, chronic ethanol induced the accumulation of apoptotic cells and fibrogenic responses in the liver of FD−/−mice. These data highlight the protective role of complement factor D (FD) and suggest that FD-dependent amplification of complement is an adaptive response that promotes hepatic healing and recovery in response to chronic ethanol.NEW & NOTEWORTHY Complement, a component of the innate immune system, is an important pathophysiological contributor to ethanol-induced liver injury. We have identified a novel role for factor D, a component of the alternative pathway, in protecting the liver from ethanol-induced inflammation, accumulation of apoptotic hepatocytes, and profibrotic responses. These data indicate a dual role of complement with regard to inflammatory and protective responses and suggest that accumulation of apoptotic cells impairs hepatic healing/recovery during alcoholic liver disease.